(Q37795874)

23 August 2017

title

Glycaemic control with liraglutide: the phase 3 trial programme (English)

1 reference

23 August 2017

main subject

phase III clinical trial

0 references

1 reference

P. Raskin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20887301

24 July 2024

P. F. Mora

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20887301

24 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20887301

24 July 2024

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

https://doi.org/10.1111/j.1742-1241.2010.02496.x

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20887301

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1742-1241.2010.02496.x

24 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1742-1241.2010.02496.x/fullpdf

24 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

International journal of clinical practice. Supplement

24 July 2024

published in

1 reference

23 August 2017

issue

167

1 reference

23 August 2017

page(s)

21-27

1 reference

NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Circulation and degradation of GIP and GLP-1.

24 July 2024

2

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

24 July 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

24 July 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

24 July 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

24 July 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

24 July 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

24 July 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

24 July 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

24 July 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

24 July 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

24 July 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

24 July 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

24 July 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

24 July 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

24 July 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

24 July 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

24 July 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

24 July 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02496.X

24 July 2024

Identifiers

1 reference

23 August 2017

1 reference